Mouse VEGFR1/Flt-1 Antibody

Catalog # Availability Size / Price Qty
AF471
AF471-SP
Mouse VEGFR1/Flt-1 Antibody in Data
1 Image
Product Details
Citations (27)
FAQs
Supplemental Products
Reviews

Mouse VEGFR1/Flt-1 Antibody Summary

Species Reactivity
Mouse
Specificity
Detects mouse VEGFR1/Flt-1 in ELISAs and Western blots. In sandwich ELISAs, approximately 7% cross-reactivity with recombinant human VEGFR1 is observed, approximately 4% cross-reactivity with recombinant mouse (rm) VEGF164 is observed, less than 1% cross-reactivity with recombinant rat VEGF164 is observed, and less than 0.2% cross-reactivity with rmVEGFR2 and rmVEGFR3 is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
Mouse myeloma cell line NS0-derived recombinant mouse VEGFR1/Flt-1
Ser27-Glu759
Accession # P35969
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
0.1 µg/mL
Recombinant Mouse VEGFR1/Flt‑1 Fc Chimera (Catalog # 471-F1)
Flow Cytometry
2.5 µg/106 cells
bEnd.3 mouse endothelioma cell line
Blockade of Receptor-ligand Interaction
In a functional ELISA, 1-4 µg/mL of this antibody will block 50% of the binding of 10 ng/mL of Recombinant Mouse PlGF-2 (Catalog # 465-PL) to immobilized Recombinant Mouse VEGFR1/Flt-1 Fc Chimera (Catalog # 471-F1) coated at 1 µg/mL (100 µL/well). At 50 μg/mL, this antibody will block >90% of the binding.
 
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 

Mouse VEGFR1/Flt-1 Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
0.2-0.8 µg/mL 

Use in combination with:

Detection Reagent: Mouse VEGFR1/Flt-1 Biotinylated Antibody (Catalog # BAF471)

Standard: Recombinant Mouse VEGFR1/Flt-1 Fc Chimera Protein, CF (Catalog # 471-F1)

Neutralization
Measured by its ability to neutralize VEGF164-induced proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 2-8 µg/mL in the presence of 5 ng/mL Recombinant Mouse VEGF164.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Example

Neutralization Cell Proliferation Induced by VEGF<sub>164</sub>and Neutralization by Mouse VEGFR1/Flt‑1 Antibody. View Larger

Cell Proliferation Induced by VEGF164and Neutralization by Mouse VEGFR1/Flt‑1 Antibody. Recombinant Mouse VEGF164(Catalog # 493-MV) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse VEGF164(5 ng/mL) is neutralized (green line) by increasing concentrations of Mouse VEGFR1/Flt-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF471). The ND50is typically 2-8 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR1/Flt-1

VEGFR1 is one of the five receptor tyrosine kinases (RTKs) (VEGFR1, KDR/Flk-1, Flt-4, Tie-1, and Tek/Tie-2) whose expression is almost exclusively restricted to the endothelial cells. Tie-1 and tek/tie-2 define a new class of RTKs containing two immunoglobulin-like domains, three EGF homology domains and three fibronectin type III domains in their extracellular regions. VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4 are members of the class III subfamily of RTKs containing seven immunoglobulin-like repeats in their extracellular domains. All five RTKs are likely to play central roles in vasculogenesis and angiogenesis.

Full length mouse VEGFR1 mRNA encodes a 1333 amino acid (aa) residue precursor with a predicted 22 aa residue signal peptide. Mature VEGFR1 is composed of a 737 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 552 aa residue cytoplasmic domain. As a result of alternative splicing of the mRNA, a cDNA encoding a truncated form of VEGFR1, lacking the seventh immunoglobulin-like domain, the transmembrane and intracellular domains, has been cloned. The recombinant soluble VEGFR1/Fc chimera binds VEGF and PlGF with high affinity and is a potent VEGF antagonist.

References
  1. He, Y. et al. (1999) Molecular Endocrinology 13:537.
  2. Ferrara, N. and T. Davis-Smyth (1997) Endocrine Reviews 8:4.
Long Name
Vascular Endothelial Growth Factor Receptor 1
Entrez Gene IDs
2321 (Human); 14254 (Mouse)
Alternate Names
EC 2.7.10; EC 2.7.10.1; FLT; FLT1; Flt-1; Fms-like tyrosine kinase 1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor); FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; vascular endothelial growth factor receptor 1; Vascular permeability factor receptor; VEGF R1; VEGFR1; VEGFR-1

Product Datasheets

Citations for Mouse VEGFR1/Flt-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

27 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy
    Authors: M Verma, Y Shimizu-Mo, Y Asakura, JP Ennen, J Bosco, Z Zhou, GH Fong, S Josiah, D Keefe, A Asakura
    PLoS Genet., 2019;15(12):e1008468.
    Species: Mouse
    Sample Types: Tissue
    Applications: IHC frozen fixed
  2. Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineering
    Authors: F Zhao, L Zhou, J Liu, Z Xu, W Ping, H Li, L Xu, Z Xu, C Zhou, M Wang, R Jia
    J Tissue Eng, 2019;10(0):2041731419891.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Neutralization
  3. Mechanistic Insights into the Anti-angiogenic Activity of Trypanosoma cruzi Protein 21 and its Potential Impact on the Onset of Chagasic Cardiomyopathy
    Authors: SC Teixeira, DS Lopes, SN Gimenes, TL Teixeira, MS da Silva, RT Brígido, FA da Luz, AA da Silva, MA Silva, PV Florentino, PC Tavares, MA Dos Santos, VM Ávila, MJ Silva, MC Elias, RA Mortara, CV da Silva
    Sci Rep, 2017;7(0):44978.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  4. PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia
    Nat Commun, 2016;7(0):13650.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  5. Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage.
    Authors: Hou, Sheng Ta, Nilchi, Ladan, Li, Xuesheng, Gangaraju, Sandhya, Jiang, Susan X, Aylsworth, Amy, Monette, Robert, Slinn, Jacqueli
    Sci Rep, 2015;5(0):7890.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Differential apicobasal VEGF signaling at vascular blood-neural barriers.
    Authors: Hudson N, Powner M, Sarker M, Burgoyne T, Campbell M, Ockrim Z, Martinelli R, Futter C, Grant M, Fraser P, Shima D, Greenwood J, Turowski P
    Dev Cell, 2014;30(5):541-52.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  7. Nonmuscle myosin light-chain kinase mediates microglial migration induced by HIV Tat: involvement of beta1 integrins.
    Authors: Yao H, Duan M, Yang L, Buch S
    FASEB J, 2013;27(4):1532-48.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Neutralization
  8. The role of IL-1beta in the early tumor cell-induced angiogenic response.
    Authors: Carmi Y, Dotan S, Rider P, Kaplanov I, White M, Baron R, Abutbul S, Huszar M, Dinarello C, Apte R, Voronov E
    J Immunol, 2013;190(7):3500-9.
  9. The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy.
    Authors: Schreurs MP, Houston EM, May V, Cipolla MJ
    FASEB J., 2012;26(1):355-62.
    Species: Rat
    Sample Types: In Vivo
    Applications: Neutralization
  10. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.
    Authors: Benedito R, Rocha S, Woeste M, Zamykal M, Radtke F, Casanovas O, Duarte A, Pytowski B, Adams R
    Nature, 2012;484(7392):110-4.
    Species: Mouse
    Sample Types: Tissue Homogenates
    Applications: Immunoprecipitation
  11. Hypoxia-inducible factor-2alpha regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis.
    Authors: Roda JM, Sumner LA, Evans R, Phillips GS, Marsh CB, Eubank TD
    J. Immunol., 2011;187(4):1970-6.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization
  12. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages.
    Authors: Eubank TD, Roberts RD, Khan M, Curry JM, Nuovo GJ, Kuppusamy P, Marsh CB
    Cancer Res., 2009;69(5):2133-40.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization
  13. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.
    Authors: Shin JY, Yoon IH, Kim JS, Kim B, Park CG
    Cell. Immunol., 2009;256(1):72-8.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Neutralization
  14. VEGF promotes vascular sympathetic innervation.
    Authors: Marko SB, Damon DH
    Am. J. Physiol. Heart Circ. Physiol., 2008;294(6):H2646-52.
    Species: Rat
    Sample Types: Whole Cells
    Applications: ICC
  15. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats.
    Authors: Li Y, Zhang F, Nagai N, Tang Z, Zhang S, Scotney P, Lennartsson J, Zhu C, Qu Y, Fang C, Hua J, Matsuo O, Fong GH, Ding H, Cao Y, Becker KG, Nash A, Heldin CH, Li X
    J. Clin. Invest., 2008;118(3):913-23.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization
  16. alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner.
    Authors: Zhang Z, Ramirez NE, Yankeelov TE, Li Z, Ford LE, Qi Y, Pozzi A, Zutter MM
    Blood, 2007;111(4):1980-8.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  17. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential.
    Authors: Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M, Odorisio T
    Am. J. Pathol., 2006;169(4):1167-82.
    Species: Mouse
    Sample Types: Tissue Homogenates
    Applications: ELISA Development
  18. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A.
    Authors: Nozaki M, Sakurai E, Raisler BJ, Baffi JZ, Witta J, Ogura Y, Brekken RA, Sage EH, Ambati BK, Ambati J
    J. Clin. Invest., 2006;116(2):422-9.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  19. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Authors: Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG
    Cancer Res., 2006;66(22):10919-28.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Neutralization
  20. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain.
    Authors: Le Bras B, Barallobre MJ, Homman-Ludiye J, Ny A, Wyns S, Tammela T, Haiko P, Karkkainen MJ, Yuan L, Muriel MP, Chatzopoulou E, Breant C, Zalc B, Carmeliet P, Alitalo K, Eichmann A, Thomas JL
    Nat. Neurosci., 2006;9(3):340-8.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  21. Corneal avascularity is due to soluble VEGF receptor-1.
    Authors: Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J
    Nature, 2006;443(7114):993-7.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization
  22. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation.
    Authors: Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, Carbone DP
    J. Immunol., 2005;174(1):215-22.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  23. Antagonism of vascular endothelial growth factor results in microvessel attrition and disorganization of wound tissue.
    Authors: Gudehithlu KP, Ahmed N, Wu H, Litbarg NO, Garber SL, Arruda JA, Dunea G, Singh AK
    J. Lab. Clin. Med., 2005;145(4):194-203.
    Species: Rat
    Sample Types: Whole Tissue
    Applications: IHC-P
  24. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.
    Authors: Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP
    Invest. Ophthalmol. Vis. Sci., 2004;45(2):368-74.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization
  25. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.
    Authors: Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C
    J. Cell Biol., 2003;161(6):1163-77.
    Species: Rat
    Sample Types: In Vivo
    Applications: Neutralization
  26. Vascular endothelial growth factor-B promotes in vivo angiogenesis.
    Authors: Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F, Duriez M, Schwartz B, Branellec D, Levy BI
    Circ. Res., 2003;93(2):114-23.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization
  27. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction.
    Authors: Kozawa O, Yoshimi N, Akamatsu S, Hara A, Mori H, Uematsu T
    Blood, 2002;100(7):2487-93.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Mouse VEGFR1/Flt-1 Antibody

There are currently no reviews for this product. Be the first to review Mouse VEGFR1/Flt-1 Antibody and earn rewards!

Have you used Mouse VEGFR1/Flt-1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review